Book contents
- Club Drugs and Novel Psychoactive Substances
- Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction
- Part II Stimulant Drugs
- Part III Depressant Drugs
- Chapter 12 Depressant Drugs: Introduction
- Chapter 13 Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL)
- Chapter 14 Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS
- Chapter 15 Depressant Drugs: Benzodiazepine NPS
- Chapter 16 Depressant Drugs: Ketamine and Its Analogues
- Part IV Synthetic Cannabinoid Receptor Agonists
- Part V Hallucinogens
- References
- Index
Chapter 14 - Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS
from Part III - Depressant Drugs
Published online by Cambridge University Press: 21 September 2020
- Club Drugs and Novel Psychoactive Substances
- Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction
- Part II Stimulant Drugs
- Part III Depressant Drugs
- Chapter 12 Depressant Drugs: Introduction
- Chapter 13 Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL)
- Chapter 14 Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS
- Chapter 15 Depressant Drugs: Benzodiazepine NPS
- Chapter 16 Depressant Drugs: Ketamine and Its Analogues
- Part IV Synthetic Cannabinoid Receptor Agonists
- Part V Hallucinogens
- References
- Index
Summary
This chapter looks at the misuse of two groups of synthetic opioids. The first group includes fentanyl and fentanyl analogues; the second includes other novel synthetic opioids (opioid NPS). This chapter does not address issues pertaining to the use of these substances in legitimate therapeutic and clinical contexts.
- Type
- Chapter
- Information
- Club Drugs and Novel Psychoactive SubstancesThe Clinician's Handbook, pp. 71 - 77Publisher: Cambridge University PressPrint publication year: 2020